OncoVee™-MiniPDX-Guided Anticancer Treatment for Gastric Cancer Patients With Synchronous Liver Metastases: A Retrospective Cohort Analysis.
OncoVee™-MiniPDX-Guided Anticancer Treatment for Gastric Cancer Patients With Synchronous Liver Metastases: A Retrospective Cohort Analysis.
复制标题
OncoVee™-MiniPDX 引导的同步性肝转移胃癌患者抗癌治疗：回顾性队列分析
DOI：
10.3389/fonc.2021.757383
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Wei X
中科院分区：
文献类型：
--
作者：
Ge Y;Zhang X;Liang W;Tang C;Gu D;Shi J;Wei X
据估计，35%的胃癌患者出现同步性远处转移，绝大多数患者表现为转移性肝脏疾病，如何选择最合适的药物或治疗方案对改善患者预后至关重要。我们进行了这项回顾性队列分析，以评估OncoVee™-MiniPDX引导治疗对这些患者的疗效。入组了伴有肝转移的胃癌患者（GCLM）。根据患者意愿分为MiniPDX组和对照组。在观察组中，进行OncoVee™-MiniPDX模型以筛选最敏感的药物或方案，以确定临床给药。对照组按指南常规用药，不使用MiniPDX模型。主要终点为总生存期（OS），次要结局包括客观缓解率（ORR）、疾病控制率（DCR）和无进展生存期（PFS）。共纳入68例GCLM患者，观察组21例，对照组47例。两组患者的基线特征均衡。与对照组相比，MiniPDX药物敏感性试验与靶向药物的使用增加相关（33.3% vs. 0%，p=0.032）。观察组和对照组的中位OS估计分别为9.4（95% CI，7.9-11.2）个月和7.9（95% CI，7.2-8.7）个月。单因素（对照组与MiniPDX组：HR=2.586，95% CI= 1.362-4.908，p=0.004）和多变量回归分析（对照组与MiniPDX组：校正HR（aHR）=4.288，95%CI = 1.452-12.671，p=0.008）显示观察组在OS方面的优势。同样，基于MiniPDX的方案显著改善了这些病例的PFS（中位PFS 6.7个月vs. 4.2个月，aHR=2.773，95% CI=1.532-3.983，p=0.029）。与对照组相比，MiniPDX组的ORR和DCR也有所改善（ORR：57.14 vs. 25.53%，p=0.029; DCR：85.71 vs. 68.08%，p=0.035）。OncoVee™-MiniPDX模型用于选择药物指导抗肿瘤治疗，有望延长GCLM患者的生存期，提高缓解率。需要进一步精心设计的研究来证实MiniPDX的临床益处。
It is estimated that 35% of gastric cancer patients appear with synchronous distant metastases—the vast majority of patients presenting with metastatic hepatic disease. How to choose the most appropriate drugs or regimens is crucial to improve the prognosis of patients. We conducted this retrospective cohort analysis to evaluate the efficacy of OncoVee™-MiniPDX-guided treatment for these patients. Gastric cancer patients with liver metastases (GCLM) were enrolled. Patients were divided into MiniPDX and control group according to their wishes. In the observation group, the OncoVee™-MiniPDX model was conducted to screen the most sensitive drug or regimens to determine the clinical administration. Meanwhile, patients were treated with regular medications in the control group according to the guidelines without the MiniPDX model. The primary endpoint was overall survival (OS), and the secondary outcomes included objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). A total of 68 patients with GCLM were included, with the observation and control groups of 21 and 47 patients, respectively. The baseline characteristics of patients were balanced between these two groups. MiniPDX drug sensitivity tests were associated with the increased use of targeted drugs when compared with the control group (33.3 vs. 0%, p=0.032). Median OS was estimated to be 9.4 (95% CI, 7.9–11.2) months and 7.9 (95% CI, 7.2–8.7) months in the observation and control group, respectively. Both univariate (control group vs. MiniPDX group: HR=2.586, 95% CI= 1.362–4.908, p=0.004) and multivariate regression analyses (Control group vs. MiniPDX group: adjusted HR (aHR)=4.288, 95% CI= 1.452–12.671, p=0.008) showed the superiority of the observation group on OS. Similarly, MiniPDX-based regiments significantly improve the PFS of these cases (median PFS 6.7 months vs. 4.2 months, aHR=2.773, 95% CI=1.532–3.983, p=0.029). ORR and DCR were also improved in MiniPDX group comparing with control group (ORR, 57.14 vs. 25.53%, p=0.029; DCR: 85.71 vs. 68.08%, p=0.035). OncoVee™-MiniPDX model, which was used to select drugs to guide antitumor treatment, was promising to prolong survival and improve the response rate of patients with GCLM. Further well-designed studies are needed to confirm the clinical benefits of MiniPDX.
登录
查看更多内容
影响因子：
6.2
作者：
Stebbing, Justin;Paz, Keren;Schwartz, Gary K.;Wexler, Leonard H.;Maki, Robert;Pollock, Raphael E.;Morris, Ronnie;Cohen, Richard;Shankar, Arjun;Blackman, Glen;Harding, Victoria;Vasquez, David;Krell, Jonathan;Ciznadija, Daniel;Katz, Amanda;Sidransky, David
通讯作者：
Sidransky, David
影响因子：
3.9
作者：
Williams JA
通讯作者：
Williams JA
影响因子：
5.7
作者：
Hidalgo M;Bruckheimer E;Rajeshkumar NV;Garrido-Laguna I;De Oliveira E;Rubio-Viqueira B;Strawn S;Wick MJ;Martell J;Sidransky D
通讯作者：
Sidransky D
影响因子：
3.1
作者：
Klint, Asa;Engholm, Gerda;Bray, Freddie
通讯作者：
Bray, Freddie
影响因子：
50.3
作者：
Li, Chen;Sun, Yi-Di;Zeng, Rong
通讯作者：
Zeng, Rong